Axsome Therapeutics (AXSM)
(Delayed Data from NSDQ)
$115.95 USD
-2.68 (-2.26%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $115.96 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AXSM 115.95 -2.68(-2.26%)
Will AXSM be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for AXSM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AXSM
Why Is Axsome (AXSM) Up 19.2% Since Last Earnings Report?
Axsome Shares Up 20% in a Month: How Should You Play the Stock?
AXSM: What are Zacks experts saying now?
Zacks Private Portfolio Services
AXSM Q2 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y
Here's What Key Metrics Tell Us About Axsome (AXSM) Q2 Earnings
Axsome Therapeutics (AXSM) Reports Q2 Loss, Beats Revenue Estimates
Other News for AXSM
Technical picture remains unchanged for AXSM after it falls 2.26% on September 20
Technical picture remains unchanged for AXSM after it rises 1.72% on September 18
Axsome Therapeutics: Strong Growth Trajectory and Financial Outlook Justify Buy Rating
Axsome Therapeutics, Inc. (AXSM) Presents at TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit Transcript
AXSM's price rises by 2.21% on September 18, though its technical setup remains stable.